Translational Stroke Laboratory Group (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Stroke Unit, Department of Neurology, Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain.
Neuroscience. 2024 Jul 9;550:30-42. doi: 10.1016/j.neuroscience.2024.02.017. Epub 2024 Feb 21.
The constant failure of new neuroprotective therapies for ischemic stroke has partially halted the search for new therapies in recent years, mainly because of the high investment risk required to develop a new treatment for a complex pathology, such as stroke, with a narrow intervention window and associated comorbidities. However, owing to recent progress in understanding the stroke pathophysiology, improvement in patient care in stroke units, development of new imaging techniques, search for new biomarkers for early diagnosis, and increasingly widespread use of mechanical recanalization therapies, new opportunities have opened for the study of neuroprotection. This review summarizes the main protective agents currently in use, some of which are already in the clinical evaluation phase. It also includes an analysis of how recanalization therapies, new imaging techniques, and biomarkers have improved their efficacy.
近年来,新的缺血性脑卒中神经保护治疗的屡屡失败,部分阻碍了新疗法的研发,主要是因为开发一种新疗法来治疗具有复杂病理(如脑卒中)、治疗窗口较窄和相关合并症的疾病,如脑卒中,所需的高投资风险。然而,由于近年来对脑卒中病理生理学的深入了解,脑卒中单元中患者护理的改善,新的成像技术的发展,早期诊断新生物标志物的探索,以及机械再通治疗的日益广泛应用,为神经保护的研究提供了新的机会。本综述总结了目前正在使用的主要保护剂,其中一些已经处于临床评估阶段。它还分析了再通治疗、新的成像技术和生物标志物如何提高它们的疗效。